Merck
CN

Metabolic disorders in Turkish children with urolithiasis.

Urology (2015-03-31)
Mehmet Halil Celiksoy, Alev Yilmaz, Gonul Aydogan, Aysel Kiyak, Erdem Topal, Serdar Sander
ABSTRACT

To review metabolic disorders in Turkish children with urinary tract stone disease. The medical records of 308 pediatric patients with the diagnosis of urolithiasis between 1996 and 2008, whose disease progression was followed in a single tertiary-care center, were reviewed retrospectively. Two hundred forty-eight patients whose metabolic analyses were performed were included in the study. Of the 248 patients participating in the study, 142 (57%) were men and 106 (43%) were women. The median age of the patients was 48 months (minimum-maximum, 2-180 months). Seventy-six percent of the patients had metabolic disorders. Of all patients, 44% had 1, 23% had 2, and 7% had 3 metabolic disorders. Hypercalciuria, hypocitraturia, hyperoxaluria, hyperuricosuria, and cystinuria were detected in 41%, 39%, 22%, 9%, and 4% of the patients, respectively. The rate of multiple stone formation, infection, and recurrence was significantly higher in the 0-2 years age group (P = .030, P = .001, P = .019, respectively). The median age of patients was greater (P = .001) in patients with hyperoxaluria in comparison with other metabolic disorders. Compared with other metabolic disorders, multiple stones and recurrence were more frequent in patients with cystinuria (P = .022 and P = .008, respectively). The size of the stones was greater in patients with hyperuricosuria in comparison with other metabolic disorders (P = .009). The majority of children with urinary tract stone disease exhibited ≥1 metabolic risk factors. Metabolic risk factors should be evaluated in all children with urinary stone disease to provide appropriate treatment.

MATERIALS
Product Number
Brand
Product Description

Millipore
Urea solution, suitable for microbiology, 40% in H2O
Sigma-Aldrich
Urea solution, BioUltra, ~8 M in H2O
Sigma-Aldrich
Urea-12C, 99.9 atom % 12C
Sigma-Aldrich
Urea solution, 40 % (w/v) in H2O
Urea, European Pharmacopoeia (EP) Reference Standard
USP
Urea, United States Pharmacopeia (USP) Reference Standard
Supelco
Urea, 8 M (after reconstitution with 16 mL high purity water)
Supelco
Creatinine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Urea, analytical standard
Sigma-Aldrich
Urea, Vetec, reagent grade, 99%
Sigma-Aldrich
Urea, powder, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
Uric acid, ≥99%, crystalline
Sigma-Aldrich
Creatinine, anhydrous, ≥98%
Sigma-Aldrich
Uric acid, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
Urea, BioUltra, for molecular biology, 99% (T)
Sigma-Aldrich
Urea, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99%
Sigma-Aldrich
Urea, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
Sigma-Aldrich
Urea, suitable for electrophoresis
Sigma-Aldrich
Urea, ACS reagent, 99.0-100.5%
Sigma-Aldrich
Urea, ReagentPlus®, ≥99.5%, pellets
Sigma-Aldrich
Urea, meets USP testing specifications
Sigma-Aldrich
Urea, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%, 99.0-101.0% (calc. on dry substance)